- Date 17 June 2015
- Mise à jour : 17/03/2016
- Documents : 3
- History
Listen
ENBREL (etanercept), TNF inhibitor
RHEUMATOLOGY - New indication
Opinions on drugs -
Posted on
Nov 12 2015
Reason for request
Extension of indication
No clinical benefit demonstrated by comparison with HUMIRA (adalimumab) or CIMZIA (certolizumab pergol) in the management of patients with severe non-radiographic axial spondyloarthritis with objective signs of inflammation on the failure of NSAIDs.
- ENBREL now has Marketing Authorisation in the treatment of severe non-radiographic axial spondyloarthritis in adults with objectives signs of inflammation, taking the form of an elevated level of C-reactive protein (CRP) and/or signs visible in magnetic resonance imaging (MRI), in patients with an inadequate response to non-steroidal antiinflammatories (NSAIDs).
- Since no comparison is available with other TNF inhibitors indicated in non-radiographic axial spondyloarthritis, it is not possible to rank them.
Clinical Benefit
| Substantial |
- |
Clinical Added Value
| no clinical added value |
- |
Therapeutic use
- |
English version
Contact Us
Évaluation des médicaments
